ArticleBMC surgery2026
Nasopharyngeal carcinoma radiation-induced sarcoma in the skull base: a retrospective follow-up cohort study.
Article in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiation-induced sarcoma (RIS) is a rare, fatal late complication of radiotherapy for nasopharyngeal carcinoma (NPC), particularly in the anatomically complex skull base region. Despite the high radiotherapy doses delivered to this area in NPC treatment, epidemiological features and risk factors for skull base NPC-RIS remain poorly defined, and systematic studies are lacking. Therefore, this study aimed to investigate the clinical characteristics and outcomes of skull base NPC-RIS.
methodsThis retrospective multicenter case series analyzed seven patients with pathologically confirmed skull base NPC-RIS and compared them to two control cohorts: recurrent NPC and primary T3/T4 NPC. The inclusion criteria were a primary NPC diagnosis, prior radiotherapy, new sarcoma within/adjacent to the radiation field meeting the modified Cahan criteria, and complete data. Clinical, imaging, and histopathological data were collected. The tumor location relative to the original radiation field and latency periods were analyzed.
resultsAll seven NPC-RIS tumors occurred in the skull base, originating within prior high-dose fields. All RIS were noted in patients initially with T3-4 nasopharyngeal carcinoma. The pathological types were predominantly fibrosarcoma/osteosarcoma. Patients with NPC-RIS had significantly worse survival than those with recurrent NPC and primary T3/T4 NPC. Key distinguishing features of NPC-RIS included younger age at initial radiotherapy, significantly longer latency to onset than recurrence NPC, and tumors arising outside the original NPC site but within the irradiated field.
conclusionYounger age at radiotherapy was a key risk factor. Long latency and tumor location outside the primary NPC site, but within the radiation field, are critical diagnostic indicators. Management mandates lifelong surveillance for NPC survivors and prompt biopsy of new lesions in irradiated fields.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.